Mr. Craig Milne reports

INNOVOTECH INC. REPORTS RECORD REVENUE FOR Q1-2025

Innovotech Inc. had record revenue of $1,158,185 for the period ended March 31, 2025. This surpassed the previous record revenue posted for fourth quarter 2024 of $1,045,837 and the comparable first quarter 2024 of $313,976. The strong growth is a result of increased contract research at subsidiary Innovotech Labs Corp., together with the consolidated revenues from Keystone Labs Inc. The accretive acquisition of Keystone Labs in Q4 2024 continues to contribute substantially to revenue growth, profitability and building a strong management team.

The company posted $63,523 net and comprehensive income for the period.

"Our team has managed the growth exceptionally well, continuing to deliver the quality outcomes that our clients expect and maintaining our research and development programs that will continue to drive the business forward," said Craig Milne, chief executive officer.

About Innovotech Inc.

Innovotech is a diversified Canadian technology company with business operations in a growing portfolio of specialized laboratory services, biotechnology businesses and proprietary intellectual property. Innovotech manages several subsidiary companies. Innovotech Labs is a contract research organization that owns and provides proprietary devices for anti-microbial testing in multiple applications and commercializes anti-microbial silver solutions. Keystone Labs is a DEL-accredited lab serving the Canadian pharmaceutical industry and industrial markets. Innovotech owns a 60-per-cent stake in NouLifeSciences Inc., a company holding intellectual property related to anti-oxidant molecules with potential applications in cosmetics and various medical conditions including neuropathies.

We seek Safe Harbor.